- Home
- HOPE vs CRVS Comparison
HOPE vs CRVS Comparison
Compare HOPE & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HOPE | CRVS |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2000 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HOPE | CRVS |
|---|---|---|
| Price | $10.99 | $15.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $13.75 | ★ $28.20 |
| AVG Volume (30 Days) | 706.7K | ★ 1.1M |
| Earning Date | 04-28-2026 | 06-26-2026 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 0.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.10 | N/A |
| Revenue Next Year | $10.98 | N/A |
| P/E Ratio | $22.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.83 | $2.54 |
| 52 Week High | $12.79 | $26.95 |
Technical Indicators
Market Signals| Indicator | HOPE | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 34.53 | 43.10 |
| Support Level | $10.72 | $6.65 |
| Resistance Level | $11.21 | $18.73 |
| Average True Range (ATR) | 0.30 | 0.94 |
| MACD | -0.07 | -0.32 |
| Stochastic Oscillator | 22.78 | 28.26 |
Price Performance
Historical ComparisonAbout HOPE Hope Bancorp Inc.
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services, and other banking services.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).